It’s been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...

We still have 1.3 million new infections a year, the majority of which occur in marginalised and vulnerable groups. But we ...

A new HIV prevention drug, lenacapavir, has shown 100% effectiveness in women and near-perfect results in men during trials.

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

It’s been called the closest the world has ever come to a vaccine against AIDS. The twice-yearly shot was 100% effective in ...

Dr. Reddy’s Laboratories RDY is a major player in the generic drugs markets. The company reports its financial performance ...